Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (September 2020)
28 slides from Adocia Sa's investor presentation, September 2020
Slide 1: Investors Presentation September 2020
ADOCIA Investors Presentation September 2020
Slide 2: Disclaimer
Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain performance, including its financial position, results and been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the cash flow, as well as the trends in
Slide 3: Highly Experienced Management Team
Highly Experienced Management Team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, Chief Financial Officer President & CEO Director of R&D Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy Co-found
Slide 4: Executive Summary
Executive Summary Our mission: to develop innovative formulations for the treatment of diabetes 1 and other metabolic diseases, based on insulins and other approved hormones 5 patented products with clinical stage proof-of-concept based on a unique 2 patented BioChaperone® technology platform 3 Our
Slide 5: BioChaperone platform potentializes performance of approved proteins and peptides
BioChaperone platform (BC) potentializes performance of approved proteins and peptides • 6 products based on this technology • 50 patents covering more than 500 different BioChaperone ® Sept 2020 – Investors Presentation 5
Slide 6: A well-advanced pipeline with 6 products ready to partner
A well-advanced pipeline with 6 products ready to partner Preclinic Phase I Phase II Phase III Upcoming milestones • Phase 3 in China in 2021 BC Lispro Ultra-Fast Insulin • On-going bridging study for EU/US: U100 / U200 results in Q4 2020 Insulins Combination BC Combo U200 Phase 1 in China in 2021 F
Slide 7: Diabetes, a major worldwide health issue
Diabetes, a major worldwide health issue 56M2 people treated with insulin 463M1 of diabetics live with severe people with 79%2 complications diabetes in 2019 of US adults with T1D 65%3 are overweight or obese Unmet medical need requiring strong therapeutic innovations 1 International Diabetes Federa
Slide 8: Diabetes treatment, an ecosystem undergoing mutation
Diabetes treatment, an ecosystem undergoing mutation Artificial Intelligence • Insulet $15B market cap • Tandem Pump Dexcom $37B market cap CGM Insulin and metabolic • Prandial insulin market: $9b2 hormones Smart Aug. 2020: “Medtronic to • GLP-1 market: $9b1 pen acquire Companion Medical” Our Ambiti
Slide 9: Adocia is a key player in prandial insulins
Adocia is a key player in prandial insulins Next New Multi-hormonal generation combinations Ultra Rapid insulin Rapid Acting Insulin Banting & Best Human Insulin 1920 1980 2000 2020 2025 Insulin discovery Humulin® Humalog® Fiasp® Insulin-Pram Novolin® Novolog® Lyumjev® Insuman® Apidra® BC Lispro Ado
Slide 10: Insulins + Pram Combinations provide benefits recognised by Agencies
Insulins + Pram Combinations provide benefits recognised by Agencies + Pram Pram combinations benefits: Multi-hormonal combinations ✓ Improvement of HbA1c ✓ Better glycemic control with an increase of the Time in Range ✓ Significant Weight Loss in type 1 and 2 M1 Pram Proof-of-Concept already establ
Slide 11: BC Lispro U100 & U200
BC Lispro U100 & U200 Our new generation of ultra-rapid insulins Sept 2020 – Investors Presentation
Slide 12: BC Lispro has competitive properties vs. Fiasp
BC Lispro has competitive properties vs. FiAsp® (Novo), the new “First-in-class” ultra-rapid insulin Head-to-head study BC Lispro vs. Fiasp® vs. Novolog®1 • Fast-in: faster absorption than Fiasp® to potentially reduce hyperglycemia 100 Fast-in I n s u l in C o n c e n t r a t io n (m U /L ) 90 • Fas
Slide 13: BC Lispro, a challenger on a multi-billion dollars market
BC Lispro, a challenger on a multi-billion dollars market • Only 3 ultra-rapid insulins will compete in the $9B1 prandial insulin market: o Fiasp® (Novo Nordisk) o Lyumjev® (Eli Lilly) o BC Lispro (Adocia) • Licensed to Tonghua Dongbao for the Chinese market2 with $10M upfront and $35M upcoming deve
Slide 14: BC Combo
BC Combo Our combination of glargine & lispro insulins Sept 2020 – Investors Presentation
Slide 15: BC Combo combines simplicity of use and performance of modern insulins
BC Combo combines simplicity of use and performance of modern insulins: glargine and lispro Less hyperglycemia Less hypoglycemia Trial in 28 people with T1D (NCT#02514954); * p=3.10-3;**p=8.10-3 BC Combo offers better performance than Humalog Mix, current standard of care on the premix market 1. T1D
Slide 16: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China • Targeting a $2.5B1 global premix market Tonghua Dongbao in short: • Focused on the Chinese market, where 65% of • 78%3 of revenue from insulin insulin consumption is premix first line • $4.4Bn Market cap (Sep 2020) • Licensed to Tonghua Dongbao for
Slide 17: M1Pram & BC LisPram / BC AsPram
M1Pram & BC LisPram / BC AsPram Insulin-pram combinations a therapeutic breakthrough Sept 2020 – Investors Presentation
Slide 18: Pramlintide is a key hormone in glycemic control
Pramlintide is a key hormone in glycemic control Activates amylin receptors in different brain areas ▪ Satiety ▪ Well-being ▪ Protects cognitive functions Inhibits pancreatic alpha cells glucagon secretion ▪ Better glycemic control ▪ Lower PPG rise ▪ Reduction of insulin dose Restores normal time of
Slide 19: Adocia is developing 3 insulin-pram combinations for pen and pump
Adocia is developing 3 insulin-pram combinations for pen and pump M1Pram BC LisPram / BC AsPram human insulin analog + pram rapid insulin analog + pram designed for pen designed for PUMP • M1Pram has the optimal product profile for • BC LisPram / BC AsPram are intended to be MDI the perfect pump ins
Slide 20: M1Pram Phase Ib (part B) demonstrates strong clinical benefits
M1Pram Phase Ib (part B) demonstrates strong clinical benefits in patients with BMI >25 kg/m² Delays and reduces Mean blood glucose postprandial glucose reduced by 7 mg/dL excursions Glycemic control • Mean daily “tight” TIR [80-140] mg/dL Improves glucose improved by 63 min -7 mg/dL homeostasis, TI
Slide 21: M1Pram offers better glycemic control and weight loss
M1Pram offers better glycemic control and weight loss “This combination has the potential to M1Pram leverages pramlintide’s clinical benefits finally deliver on the promise of pramlintide for a large number of ✓ Flatter Post Prandial Glycemia patients” ✓ A1c decrease (simulated) Prof. Robert Ratner,
Slide 22: Academic proof-of-concept for rapid insulin + pram in artificial pancreas
Academic proof-of-concept for rapid insulin (Lispro) + pram in artificial pancreas Dr. A. Haidar (Mc Gill University) has treated 29 T1D using Lispro+Pram vs. Lispro using artificial pancreas ✓ Lispro + pram together attain 84% Time-in-Range over one month1 vs 74% for Lispro (Humalog) Lispro Lispro
Slide 23: BC LisPram / BC AsPram, the Perfect Pump Insulin
BC LisPram / BC AsPram, the Perfect Pump Insulin ▪ BC LisPram / BC AsPram are developed for insulin "A co-formulation of insulin and pramlintide pumps like BC LisPram should allow us to see the ▪ Data package is completed to launch a clinical same performance with a single pump. That proof of concep
Slide 24: Our insulin-pram combinations address a 30 million patient population
Our insulin-pram combinations address a 30 million patient population worldwide 25 million1 of type 1 diabetes patients could benefit from our insulin-pram combinations as a 1st line of treatment 5 million type 2 diabetes patients becoming progressively “type-1-like” patient over the evolution of th
Slide 25: News flow
News flow BC Lispro M1Pram BC LisPram/Aspram • In China: Phase 3 launch • Results of the Phase 1b • Launch of a clinical Ph1 study planned in 2021 clinical study published Sept. in TD1 pump: Q1 2021 15, 2020 • For US, Europe and Japan: results of the on-going • Launch a clinical Ph2 study in bridgin
Slide 26: Key financials & Shareholder Information
Key financials & Shareholder Information (as of August 2020) Market information Shareholder ownership Key financials • Listed on Euronext Paris (ADOC) • 6.9M shares outstanding Soula Family • €85M raised since inception 22,1% • ADR program in the US (ADOCY) • Cash position: €38M • Debt: €27M Free fl
Slide 27: Summary
Summary • Adocia has 6 ready-to-license products with clinical proof-of-concept based on its proprietary BioChaperone platform • Tonghua Dongbao partnership is progressing well with up to $85M development milestone to come • BC Lispro is one of the three Ultra Rapid Insulin for prandial insulin mark
Slide 28: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 [email protected] Sept 2020 – Investors Presentation